Impactiviti Daily 120909 posted on December 9, 2009TODAY’S NEWS Novartis' "son of Glivec" (Tasigna) carrying on the family tradition - Novartis has reported result of Tasigna Phase III clinical trial. In the study, Tasigna (nilotinib) demonstrated …Continue Reading about Impactiviti Daily 120909 →